267 related articles for article (PubMed ID: 37675342)
1. Plant-derived compounds for treating autosomal dominant polycystic kidney disease.
Zhang J; Chen J; Xu J; Xue C; Mao Z
Front Nephrol; 2023; 3():1071441. PubMed ID: 37675342
[TBL] [Abstract][Full Text] [Related]
2. Applications of Herbal Medicine to Treat Autosomal Dominant Polycystic Kidney Disease.
Shao G; Zhu S; Yang B
Front Pharmacol; 2021; 12():629848. PubMed ID: 33986666
[TBL] [Abstract][Full Text] [Related]
3. Nutraceutical for Autosomal Dominant Polycystic Kidney Disease Therapy.
Yuajit C; Chatsudthipong V
J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S97-103. PubMed ID: 26817244
[TBL] [Abstract][Full Text] [Related]
4. The Clinical Manifestation and Management of Autosomal Dominant Polycystic Kidney Disease in China.
Xue C; Zhou CC; Wu M; Mei CL
Kidney Dis (Basel); 2016 Oct; 2(3):111-119. PubMed ID: 27921038
[TBL] [Abstract][Full Text] [Related]
5. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis.
He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B
Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678
[TBL] [Abstract][Full Text] [Related]
6. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease.
Yuajit C; Muanprasat C; Gallagher AR; Fedeles SV; Kittayaruksakul S; Homvisasevongsa S; Somlo S; Chatsudthipong V
Biochem Pharmacol; 2014 Apr; 88(3):412-21. PubMed ID: 24518257
[TBL] [Abstract][Full Text] [Related]
7. Clinical Manifestation and Management of ADPKD in Western Countries.
Sommerer C; Zeier M
Kidney Dis (Basel); 2016 Oct; 2(3):120-127. PubMed ID: 27921039
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
9. [Tolvaptan, a vasopressin V
Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y
Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456
[TBL] [Abstract][Full Text] [Related]
10. Autosomal dominant polycystic kidney disease: updated perspectives.
Rastogi A; Ameen KM; Al-Baghdadi M; Shaffer K; Nobakht N; Kamgar M; Lerma EV
Ther Clin Risk Manag; 2019; 15():1041-1052. PubMed ID: 31692482
[TBL] [Abstract][Full Text] [Related]
11. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model.
Bennett H; McEwan P; Hamilton K; O'Reilly K
BMC Nephrol; 2019 Apr; 20(1):136. PubMed ID: 31014270
[TBL] [Abstract][Full Text] [Related]
12. [Research progress in autosomal dominant polycystic kidney disease].
Hu S; Li D; Tan X; Gu J; Chen M; Zhang X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 44(10):1179-1187. PubMed ID: 31857514
[TBL] [Abstract][Full Text] [Related]
13. Natural-derived compounds and their mechanisms in potential autosomal dominant polycystic kidney disease (ADPKD) treatment.
Mahendran R; Lim SK; Ong KC; Chua KH; Chai HC
Clin Exp Nephrol; 2021 Nov; 25(11):1163-1172. PubMed ID: 34254206
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
Liu Y; Dai B; Fu L; Jia J; Mei C
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794
[TBL] [Abstract][Full Text] [Related]
15. Ganoderma triterpenes retard renal cyst development by downregulating Ras/MAPK signaling and promoting cell differentiation.
Su L; Liu L; Jia Y; Lei L; Liu J; Zhu S; Zhou H; Chen R; Lu HAJ; Yang B
Kidney Int; 2017 Dec; 92(6):1404-1418. PubMed ID: 28709639
[TBL] [Abstract][Full Text] [Related]
16. Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon.
Zhou JX; Torres VE
Adv Kidney Dis Health; 2023 May; 30(3):245-260. PubMed ID: 37088527
[TBL] [Abstract][Full Text] [Related]
17. Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?
Pisani A; Riccio E; Bruzzese D; Sabbatini M
BMC Nephrol; 2018 Oct; 19(1):282. PubMed ID: 30348113
[TBL] [Abstract][Full Text] [Related]
18. Tolvaptan in Pediatric Autosomal Dominant Polycystic Kidney Disease: From Here to Where?
Liu F; Feng C; Shen H; Fu H; Mao J
Kidney Dis (Basel); 2021 Sep; 7(5):343-349. PubMed ID: 34604341
[TBL] [Abstract][Full Text] [Related]
19. Goat's rue - French lilac - Italian fitch - Spanish sainfoin: gallega officinalis and metformin: the Edinburgh connection.
Hadden DR
J R Coll Physicians Edinb; 2005 Oct; 35(3):258-60. PubMed ID: 16402501
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
Messchendorp AL; Casteleijn NF; Meijer E; Gansevoort RT
Nephrol Dial Transplant; 2020 Aug; 35(8):1306-1316. PubMed ID: 31077332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
